Serine protease inhibitors and cytotoxic T lymphocytes

被引:0
|
作者
Ashton-Rickardt, Philip G. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Immunol, London W12 0NN, England
基金
英国惠康基金; 美国国家卫生研究院; 英国医学研究理事会;
关键词
serine protease inhibitors; cytotoxic T cells; apoptosis; GRANZYME-B INHIBITOR; CELLS IN-VIVO; RENAL-ALLOGRAFT REJECTION; PERFORIN-DEFICIENT MICE; MEDIATED CYTOTOXICITY; VIRAL-INFECTION; DENDRITIC CELLS; STEM-CELLS; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Serine proteases control a wide variety of physiological and pathological processes in multi-cellular organisms, including blood clotting, cancer, cell death, osmoregulation, tissue remodeling, and immunity to infection. Cytotoxic T lymphocytes (CTLs) are required for adaptive cell-mediated immunity to intracellular pathogens by killing infected cells and through the development of memory T cells. Serine proteases not only allow a CTL to kill but also impose homeostatic control on CTL number. Serine protease inhibitors (serpins) are the physiological regulators of serine proteases' activity. In this review, I discuss the role of serpins in controlling the recognition of antigen, effector function, and homeostatic control of CTLs through the inhibition of physiological serine protease targets. An emerging view of serpins is that they are important promoters of cellular viability through their inhibition of executioner proteases. This view is discussed in the context of the T-lymphocyte survival during effector responses and the development and persistence of long-lived memory T cells. Given the important role serpins play in CTL immunity, I discuss the potential for developing new immunotherapeutic approaches based directly on serpins or knowledge gained from identifying their physiologically relevant protease targets.
引用
收藏
页码:147 / 158
页数:12
相关论文
共 50 条
  • [41] Neutral inhibitors of the serine protease factor Xa
    Shrader, WD
    Young, WB
    Sprengeler, PA
    Sangalang, JC
    Elrod, K
    Carr, G
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) : 1801 - 1804
  • [42] CLONING AND ANTIGENIC DETERMINANTS OF SERINE PROTEASE INHIBITORS
    WACHTER, A
    PERRIN, P
    SCHECHTER, N
    KAHN, S
    ZWEIMAN, B
    RUBIN, H
    PHILLIPS, SM
    ANNALS OF ALLERGY, 1987, 58 (04): : 294 - 294
  • [43] DESIGN STRATEGIES FOR SERINE-PROTEASE INHIBITORS
    RIPKA, WC
    FASEB JOURNAL, 1995, 9 (06): : A1253 - A1253
  • [44] Recent Advances in Coagulation Serine Protease Inhibitors
    Smallheer, Joanne M.
    Quan, Mimi L.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 44, 2009, 44 : 189 - 208
  • [45] Editorial: Serine protease inhibitors and their therapeutic applications
    Crocetti, Letizia
    Quinn, Mark T.
    Cilibrizzi, Agostino
    Giovannoni, Maria Paola
    FRONTIERS IN CHEMISTRY, 2022, 10
  • [46] RESISTANCE OF CYTOTOXIC LYMPHOCYTES-T TO LYSIS BY A CLONE OF CYTOTOXIC LYMPHOCYTES-T
    KRANZ, DM
    EISEN, HN
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (10) : 3375 - 3379
  • [47] Selective inhibitors of the herpesvirus serine protease assemblin
    Flynn, DL
    Becker, DP
    Hippenmeyer, P
    Hockerman, S
    Houseman, K
    Moormann, A
    Rankin, A
    Williams, K
    Wittwer, A
    Zablocki, J
    Wiegand, R
    Holwerda, B
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 241 - MEDI
  • [48] Microbial serine protease inhibitors and their therapeutic applications
    Harish, B. S.
    Uppuluri, Kiran Babu
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 107 : 1373 - 1387
  • [49] Potential inhibitors of HCMV serine protease.
    Liotta, DC
    Snyder, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 28 - CARB
  • [50] The native metastability and misfolding of serine protease inhibitors
    Cho, YL
    Chae, YK
    Jung, CH
    Kim, MJ
    Na, YR
    Kim, YH
    Kang, SJ
    Im, H
    PROTEIN AND PEPTIDE LETTERS, 2005, 12 (05): : 477 - 481